This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LeadingBiotech: Cancer Advance
March 5, 2020
Koch Institute for Integrative Cancer Research at MITCambridge, MA

David Fabrizio
Vice President, Translational Strategy at Foundation Medicine


David Fabrizio serves as the Vice President of Translational Strategy at Foundation Medicine in Cambridge, MA. Under David’s leadership, Foundation Medicine has pioneered new genomic biomarkers for immunotherapy, including tumor mutational burden (TMB), and launched the first comprehensive genomic profiling test approved by the FDA, FoundationOne CDx. David also led the development of the first blood-based assay to determine immunotherapy response, published in Nature Medicine, which was also selected as one of Nature’s most notable advances of 2018. David completed his scientific training at the University of Vermont and subsequently studied in the lab of Dr. Lin at Harvard Medical School. He holds nine different patents or patent applications for therapeutic and diagnostic methods for cancer, as well as over 25 publications in peer reviewed journals including Nature, Cell, and the Journal of American Medical Association (JAMA), and is a member of ASCO and AACR.

Agenda Sessions

  • Looking Towards a Future of Cancer Diagnostics and Precision Medicine